DOCSLIB.ORG

And Radiation Therapy Sensitizing Strategies in Tumours with Focus on Effects of Phenothiazines on Dna Damage Response Signalling

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
And Radiation Therapy Sensitizing Strategies in Tumours with Focus on Effects of Phenothiazines on Dna Damage Response Signalling From DEPARTMENT OF ONCOLOGY-PATHOLOGY Karolinska Institutet, Stockholm, Sweden ANALYSIS AND CHARACTERIZATION OF CHEMO- AND RADIATION THERAPY SENSITIZING STRATEGIES IN TUMOURS WITH FOCUS ON EFFECTS OF PHENOTHIAZINES ON DNA DAMAGE RESPONSE SIGNALLING Katarzyna Zielinska-Chomej Stockholm 2015 All previously published papers were reproduced with permission from the publisher. Published by Karolinska Institutet. Printed by E-Print AB 2015 © Katarzyna Zielinska-Chomej, 2015 ISBN 978-91-7549-898-0 Analysis and characterization of chemo- and radiation therapy sensitizing strategies in tumours with focus on effects of phenothiazines on DNA damage response signalling THESIS FOR DOCTORAL DEGREE (Ph.D.) Dept of Oncology-Pathology, Cancer Center Karolinska (CCK) Lecture Hall, R8:00, Karolinska University Hospital, Stockholm Friday, the 16th of October, 2015, at 09:00 By Katarzyna Zielinska-Chomej Principal Supervisor: Opponent: Kristina Viktorsson, PhD Associate Prof Karin Roberg, MD, PhD Karolinska Institutet Linköping University Department of Oncology-Pathology Department of Clinical and Experimental Medicine Division of Otorhinolaryngology Co-supervisor(s): Petra Hååg, PhD Examination Board: Karolinska Institutet Associate Prof Marika Nestor, MD, PhD Department of Oncology-Pathology Uppsala University Department of Surgical Sciences, Otolaryngology and Head & Neck Surgery and Department of Professor Rolf Lewensohn, MD, PhD Immunology, Genetics and Pathology Karolinska Institutet Division of Biomedical Radiation Sciences Department of Oncology-Pathology Professor Olle Larsson, MD, PhD Karolinska Institutet Dali Zong, PhD Department of Oncology-Pathology National Cancer Institute, National Institute of Health, USA Professor Óscar Fernandez-Capetillo, PhD Laboratory of Genome Integrity Karolinska Institutet Department of Medical Biochemistry and Biophysics Division of Translational Medicine and Chemical Biology To My Beloved Ones ABSTRACT Cancer is, despite rapid progress in development of new targeted therapies, still mainly treated with surgery, chemotherapy and/or radiation therapy. The last two mentioned conventional therapies often meet general obstacles such as normal cell toxicity and tumour cell resistance. Further efforts are, hence, required to increase efficacy of both radiotherapy and chemotherapy in order to increase patients survival. In this thesis, we analysed and characterised strategies to improve chemotherapy and radiation therapy sensitivity in tumours, with focus on lung cancer. Particle radiation therapy offers an opportunity to overcome tumours' resistance to conventional photon irradiation. Unfortunately, treatment planning systems describing parameters for ion irradiations, used in particle therapy centres worldwide, are still based on the survival data from conventional radiation. In Paper I, we used two mathematical models, the linear-quadratic (LQ) and the repairable-conditionally repairable damage (RCR), to compare the effects of high LET accelerated ions with those elicited by conventional low LET photons, in different types of tumour cells. We show that the data on response to low LET irradiation can be used to create models that can predict cellular response to high LET with radiobiological parameters assessed with the RCR model. Moreover, results achieved with the RCR - but not with LQ model, suggest that tumour cells with high DNA repair capacity can benefit from radiation therapy with accelerated particles. Another cancer treatment strategy presented in this thesis is focused on the use of phenothiazines, alone or as sensitizers to chemotherapy. Phenothiazines are drugs clinically used for psychiatric disorders, but which also have been shown to possess cytotoxic activity in various regimens and tumours. In Paper II, we uncovered that monotherapy with phenothiazines caused decreased cell viability and cell death of small cell lung cancer (SCLC) cells. Furthermore, we showed that lysosomal dysfunction induced by phenothiazines was responsible for the observed higher responsiveness of SCLC cells. Our studies presented a new context of use and activity of phenothiazines in tumour cells and allow for a potential treatment opportunity for SCLC. In Paper III, we showed that phenothiazines interfere with DNA damage response (DDR) machinery in tumour cells by inhibition of one of the DNA double strand breaks (DBSs) repair pathways - the non- homologous end joining (NHEJ). We demonstrated that this phenothiazine-mediated inhibition of DNA repair was associated with increased chromatin-centred DNA-PK/ATM signalling, resulting in augmented substrate phosphorylation and protracted checkpoint arrest. This novel tumour cell selective feature of phenothiazines preferentially caused chemosensitization to genotoxic agents that induce DNA DSBs, but also opens up for possible combinations with DNA repair inhibitors. In Paper IV, in silico gene expression analysis suggested similarities in mode of action between phenothiazines and epigenetic signalling modulators. Accordingly, we showed that phenothiazines can be used to treat SCLC or the epigenetically deregulated tumour cells, neuroblastoma (NB) and acute myeloid leukemia (AML), either alone or in combination with chromatin-modifying drugs. The cytotoxicity, cell death signalling and hyperactivation of DNA repair signals observed with phenothiazines in tumour cells, were comparable in magnitude with the effect of the chromatin-modifying drugs, pan-HDACi panobinostat or the BRD4 antagonist JQ1. Moreover, the model phenothiazine compound trifluoperazine, TFP, was also found to prolong phosphorylation of DNA-PKcs in chromatin fractions of SCLC cells. The tandem treatment with TFP and either panobinostat or JQ1 was also demonstrated to increase cytotoxicity and triggered both apoptotic and autophagic cell death signalling in SCLC and NB cells. Thus, our findings in Paper IV suggest a novel therapeutic utility of phenothiazines and chromatin-modifying drugs in cancer therapy. LIST OF SCIENTIFIC PAPERS I. Mohanty C.*, Zielinska-Chomej K.*, Edgren M., Hirayama R., Murakami T., Lind B., Toma-Dasu I. Predicting the Sensitivity to Ion Therapy Based on the Response to Photon Irradiation - Experimental Evidence and Mathematical Modelling. Anticancer Research 2014; 34: 2801-2806 * equal contribution II. Zong D., Zielinska-Chomej K., Juntti T., Mörk B., Lewensohn R., Hååg P., Viktorsson K. Harnessing the Lysosome-Dependent Antitumor Activity by Phenothiazines in Human Small Cell Lung Cancer. Cell Death and Disease 2014; 5, e1111; doi:10.1038/cddis.2014.56 III. Zong D., Zielinska-Chomej K., Hååg P., Yakymovych I., Lewensohn R., Viktorsson K. Phenothiazines Trigger Hyperactivation of Chromatin- Associated DNA-PK and ATM Signaling and Offer a Novel Approach to Chemotherapy Sensitization. Manuscript IV. Zielinska-Chomej K., Zong D., Lewensohn R., Viktorsson K., Hååg P. Phenothiazines Modulate Chromatin-Related Epigenetic Processes in Tumour DNA Damage Response and Offer a Novel Strategy for Cancer Therapy. Manuscript CONTENTS 1 Introduction ..................................................................................................................... 1 1.1 Cancer and need for novel therapeutic strategies ................................................. 1 1.2 Radiation therapy ................................................................................................... 2 1.2.1 Characteristics of direct and indirect action of radiation and concept of the Linear Energy Transfer (LET) .......................................... 4 1.2.2 Relative Biological Effectiveness (RBE) ................................................. 5 1.2.3 Clonogenic cell survival and mathematical models of radiation effects ......................................................................................................... 6 1.3 DNA damage response (DDR) ............................................................................. 9 1.3.1 Detection of DNA damage, cell cycle arrest and chromatin remodelling .............................................................................................. 10 1.3.2 DNA Double Strand Breaks (DSBs) repair ............................................ 12 1.3.3 Fate of the cells with DNA damage ........................................................ 15 1.4 DDR signalling in cancer and as a target for cancer therapy ............................. 17 1.4.1 DDR as a barrier against cancer ............................................................. 17 1.4.2 DDR signalling as a target for cancer therapy ....................................... 18 1.5 Phenothiazines in psychiatry and anticancer therapy ......................................... 21 1.5.1 Development of phenothiazines as antipsychotic drugs and their targets ....................................................................................................... 21 1.5.2 Phenothiazines as dopamine antagonists and beyond ............................ 22 1.5.3 Phenothiazines targets outside the neuronal system .............................. 23 1.5.4 Phenothiazines as anticancer agents ....................................................... 23 2 Aims ............................................................................................................................... 25 3 Materials and Methods .................................................................................................. 26 4 Results and Discussion .................................................................................................
Load more

Recommended publications
  • Alzheimer's Disease, a Decade of Treatment: What Have We Learned?
    A Critical Look at Medication Dementia: Alzheimer’s Disease Management Issues in Alzheimer’s Disease R.Ron Finley, B.S. Pharm., R.Ph,CGP Lecturer (Emeritus) and Assistant Clinical Professor, UCSF School of Pharmacy Clinical Pharmacist, UCSF Memory and Aging Center- Alzheimer’s Research Center Educational Objectives Disclosures 1. Define the role for cholinesterase inhibitors in the management of Alzheimer’s disease, Lewy Body dementia, Frontal Temporal Lobe dementia. Pfizer Speakers Bureau 2. Name three common side effects of atypical antipsychotic Forest Speakers Bureau drugs. Novartis Speakers Bureau 3. Construct a pharmacological treatment plan for a 77-year-old Rx Consultant Associate Editor patient diagnosed with Alzheimer’s disease and hallucinations. WindChime Consultant 4. Describe the role for antipsychotic, antidepressant, mood HGA HealthCare Consultant stabilizers and benzodiazepines in the management of psychiatric behavior problems related to Alzheimer’s disease. Elder Care Specialist Consultant 5. Cite three potential drug or disease interactions with cholinesterase inhibitors. The Many Faces of Dementia Risk Factors Linked to AD Alzheimer’s Disease Over 65 years of age and increases Vascular: Multi-infarct with age FrontalTemporal Lobe dementia ( FTD) and female Pick’s disease Head injury Lewy Body Dementia Progressive Supranuclear Palsy Factors associated with DM, HTN, CVD Corticobasal Degeneration Genetic: family history, specific Primary Progressive Aphasia chromosome mutations Huntington’s disease
    [Show full text]
  • Synthetic Drugs
    Comprehensive and Confident Identification of Narcotics, Steroids and Pharmaceuticals in Urine David E. Alonso1, Petra Gerhards2, Charles Lyle1 and Joe Binkley1 | 1LECO Corporation, St. Joseph, MI; 2LECO European LSCA Centre, Moenchengladbach, Germany Introduction Experimental Sample A (Traditional Drugs) Sample B (Synthetic Drugs) Monitoring of patients in hospitals and clinics has traditionally relied on Samples Representative Compounds Representative Compounds targeted methods of analysis. These screening methods are not Peak # Name Formula R.T. (s) Area Similarity Mass Delta (mDa) MA (ppm) 1 Creatinine ME C5H9N3O 210 1326229 800 -0.05 -0.43 • Obtained from a collaborating European hospital 3.5e6 3.0e6 Peak # Name Formula R.T. (s) Area Similarity 2 o-Ethynylaniline C8H7N 219 167436 893 0.07 0.63 1 Indole C8H7N 213 2744171 917 comprehensive and result in an incomplete picture of a patient’s 3 2-Methoxy-4-vinylphenol C H O 223 65764 805 0.11 0.73 52 patient monitoring samples 9 10 2 2 Creatinine ME C5H9N3O 216 613318 651 • 2.5e6 4 Nicotine C10H14N2 234 3249121 898 -0.21 -1.29 3 Pyridine, 2-(1-methyl-2-pyrrolidinyl)- C10H14N2 230 24869771 899 activities. Gas chromatography high resolution time-of-flight mass 3.0e6 5 Hordenin C10H15NO 274 949734 775 -0.14 -0.84 4 Parabanic acid, 1-methyl- C4H4N2O3 233 434278 764 Sample preparation 5 Cotinine C10H12N2O 336 27810908 918 • 6 Methylecgonine C10H17NO3 276 104640 835 -0.22 -1.1 spectrometry (GC-HRT) provides a fast and convenient method for 2.0e6 5 6 Caffeine C8H10N4O2 371 3753598 797 2.5e6 7 4-(3-Pyridyl-tetrahydrofuran-2-one C9H9NO2 313 93817 849 -0.11 -0.68 3,4 7 1-methyl-7H-xanthine C6H6N4O2 437 4868196 850 analysis of urine samples.
    [Show full text]
  • THE POSSIBLE ROLE of LEUKOCYTE-GENERATED Reactrve INTERMEDIATES in the DRUG-INDUCED Agrancnocytosis
    THE POSSIBLE ROLE OF LEUKOCYTE-GENERATED REACTrVE INTERMEDIATES IN THE DRUG-INDUCED AGRANCnOCYTOSIS Zhao Chao Liu A thesis submitted in conformity with the requirements for the degree of Doctor of Philosophy Faculty of Pharmacy University of Toronto O Copyright by Zhao Chao Liu 1997 National Library Bibliothèque nationale (*m of Canada du Canada Acquisitions and Acquisitions et Bibliographic Services services bibliographiques 395 Wellington Street 395, rue Wellington Ottawa ON K1A ON4 Ottawa ON KIA ON4 Canada Canada The author has granted a non- L'auteur a accordé une licence non exclusive licence allowing the exclusive permettant a la National Library of Canada to Bibliothèque nationale du Canada de reproduce, loan, distribute or seil reproduire, prêter, distribuer ou copies of this thesis in microform, vendre des copies de cette thèse sous paper or electronic formats. la fome de microfiche/£ïlm, de reproduction sur papier ou sur format électronique. The author retains ownership of the L'auteur conserve la propriété du copyright in this thesis. Neither the droit d'auteur qui protège cette thèse. thesis nor substantial extracts fkom it Ni la thèse ni des extraits substantiels may be printed or otherwise de celle-ci ne doivent être imprimés reproduced without the author's ou autrement reproduits sans son permission. autorisation. ABSTRACT Ticlopidine and clczapine are associated with relatively high incidences of agranulocytosis. 5-aminosalicylic acid (5-ASA) is an agent widely used in the treatment of inflammatory bowel disease. It has been demonstrated that many drugs associated with drug-induced agranulocytosis or dmg-induced lupus are oxidized by activated neutrophils to reactive intermediates, by the combination of myeloperoxidase (MPO), hydrogen peroxide and chloride ion, or simply by hypochlorous acid (HOCI).
    [Show full text]
  • Clozapine-Induced Toxicity Via Induction of Oxidative Stress and Mitochondrial Dysfunction in Human Blood Lymphocytes and Protecting Role of L-Carnitine
    Original Research Article 2020;3(1):e9 Clozapine-induced Toxicity via Induction of Oxidative Stress and Mitochondrial Dysfunction in Human Blood Lymphocytes and Protecting role of L-Carnitine a b c,d a b* Ahmad Salimi , Farnaz Imani , Zhaleh Jamali , Negar Ahvar , Jalal Pourahmad a. Department of Pharmacology and Toxicology, School of Pharmacy, Ardabil University of Medical Sciences, Ardabil, Iran. b. Department of Pharmacology and Toxicology, Faculty of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran. c. Student Research Committee, School of Medicine, Shahroud University of Medical Sciences, Shahroud, Iran. d. Department of Addiction Studies, School of Medicine, Shahroud University of Medical Sciences, Shahroud, Iran. Article Info: Abstract: Received: September 2020 Clozapine is a useful antipsychotic drug but with serious, life threatening toxicity Accepted: September 2020 effects. The aim of this study is to assess the direct cytotoxicity effect of clozapine Published online: (CLZ) on human blood lymphocytes and investigate the protective effect of L‐carnitine October 2020 (LC) against clozapine‐induced cytotoxicity. Clozapine at 70 μM concentration induced cytotoxicity following 12 h. The Clozapine induced cytotoxicity was associated with intracellular reactive oxygen species (ROS) generation, mitochondrial * Corresponding Author: membrane potential (MMP) collapse, lysosomal membrane injury, lipid peroxidation, Jalal Pourahmad Email: and depletion of glutathione (GSH) and raising of oxidized glutathione (GSSG). We [email protected] showed that LC (1 mM) has a beneficial cytoprotective effect against clozapine- induced toxicity. Summery, clozapine causes organelles damages and triggers oxidative stress in lymphocytes. These data suggest that using of L‐carnitine could be useful for prevention and treatment of clozapine toxicity.
    [Show full text]
  • Drug Distribution Into Peripheral Nerve S
    Supplemental material to this article can be found at: http://jpet.aspetjournals.org/content/suppl/2018/03/06/jpet.117.245613.DC1 1521-0103/365/2/336–345$35.00 https://doi.org/10.1124/jpet.117.245613 THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS J Pharmacol Exp Ther 365:336–345, May 2018 Copyright ª 2018 by The American Society for Pharmacology and Experimental Therapeutics Drug Distribution into Peripheral Nerve s Houfu Liu, Yan Chen, Liang Huang, Xueying Sun, Tingting Fu, Shengqian Wu, Xiaoyan Zhu, Wei Zhen, Jihong Liu, Gang Lu, Wei Cai, Ting Yang, Wandong Zhang, Xiaohong Yu, Zehong Wan, Jianfei Wang, Scott G. Summerfield, Kelly Dong, and Georg C. Terstappen Department of Mechanistic Safety and Disposition (H.L., X.S., T.F., S.W.), Bioanalysis, Immunogenicity and Biomarkers (L.H., X.Z., K.D.), Integrated Biological Platform Sciences (Y.C., We.Z., J.L., J.W.), Brain Delivery Technologies (Wa.Z.), Platform Technology and Science (G.C.T.), and Department of Neuroexcitation Discovery Performance Unit (G.L., W.C., T.Y., X.Y., Z.W.), GlaxoSmithKline R&D, Shanghai, People’s Republic of China; and Department of Bioanalysis, Immunogenicity and Biomarkers, Platform Technology and Science, GlaxoSmithKline, Ware, United Kingdom (S.G.S.) Received October 10, 2017; accepted March 1, 2018 Downloaded from ABSTRACT Little is known about the impact of the blood–nerve barrier (BNB) P-glycoprotein (P-gp) and breast cancer resistance protein on drug distribution into peripheral nerves. In this study, we (BCRP) inhibitor, on the peripheral nerve and central nervous examined the peripheral nerve penetration in rats of 11 small- system (CNS) tissue penetration of imatinib.
    [Show full text]
  • DNA Interactions and Photocleavage by Anthracene, Acridine, and Carbocyanine-Based Chromophores
    Georgia State University ScholarWorks @ Georgia State University Chemistry Dissertations Department of Chemistry Fall 9-23-2013 DNA Interactions and Photocleavage by Anthracene, Acridine, and Carbocyanine-Based Chromophores Carla Mapp Follow this and additional works at: https://scholarworks.gsu.edu/chemistry_diss Recommended Citation Mapp, Carla, "DNA Interactions and Photocleavage by Anthracene, Acridine, and Carbocyanine-Based Chromophores." Dissertation, Georgia State University, 2013. https://scholarworks.gsu.edu/chemistry_diss/82 This Dissertation is brought to you for free and open access by the Department of Chemistry at ScholarWorks @ Georgia State University. It has been accepted for inclusion in Chemistry Dissertations by an authorized administrator of ScholarWorks @ Georgia State University. For more information, please contact [email protected]. DNA INTERACTIONS AND PHOTOCLEAVAGE BY ANTHRACENE, ACRIDINE, AND CARBOCYANINE-BASED CHROMOPHORES by CARLA TERRY MAPP Under the Direction of Dr. Kathryn B. Grant ABSTRACT The interaction of small molecules with DNA has been extensively studied and has produced a large catalogue of molecules that non-covalently bind to DNA though groove binding, intercalation, electrostatics, or a combination of these binding modes. Anthracene, acridine, and carbocyanine-based chromophores have been examined for their DNA binding properties and photo-reactivities. Their planar aromatic structures make them ideal chromophores that can be used to probe DNA structural interactions and binding patterns. We have studied DNA binding and photocleavgage properties of a bisacridine chromophore joined by a 2,6-bis(aminomethyl)pyridine copper-binding linker (Chapter II), a series of 9-aminomethyl anthracene chromophores (Chapters III and IV), both under conditions of high and low ionic strength, as well as a series of pentamethine linked symmetrical carbocyanine dyes (Chapter V).
    [Show full text]
  • Acridine: a Versatile Heterocyclic Nucleus
    Acta Poloniae Pharmaceutica ñ Drug Research, Vol. 69 No. 1 pp. 3ñ9, 2012 ISSN 0001-6837 Polish Pharmaceutical Society REVIEW ACRIDINE: A VERSATILE HETEROCYCLIC NUCLEUS RAMESH KUMAR*, MANDEEP KAUR AND MEENA KUMARI Lord Shiva College of Pharmacy, Sirsa-125055, Haryana, India Abstract: Acridine is a heterocyclic nucleus. It plays an important role in various medicines. A number of ther- apeutic agents are based on acridine nucleus such as quinacrine (antimalarial), acriflavine and proflavine (anti- septics), ethacridine (abortifacient), amsacrine and nitracine (anticancer), and tacrine. Acridine is obtained from high boiling fraction of coal tar. It is also obtained in nature from plant and marine sources. Acridine undergoes a number of reactions such as nucleophilic addition, electrophilic substitution, oxidation, reduction, reductive alkylation and photoalkylation. The present review article summarizes the synthesis, reaction, literature review and pharmaceutical importance of acridine. Keywords: acridines, cytotoxic, antiseptic, antimicrobial The synthesis of acridine and analogues has 1935 and penicillin, 1944) superseded the acridine attracted considerable attention from organic and based therapy. But in present arena, massive medicinal chemists for many years, as a number of increase in drug resistance bacterial infections has natural sources have been reported to have this het- attracted the attention toward acridine once again. In erocyclic nucleus. Chemically, acridine is an alka- the literature, it has been found that acridine deriva- loid from anthracene. It is also known by the names tives possess widely differing activities such as anti- of dibenzopyridine, 2,3,5,6-dibenzopyridine and 10- inflammatory and anticancer (3), antihelmintics (4), azaanthracene. Acridine has an irritating odor. It insectecidal, rodenticidal (5), fungicidal (6) and crystallizes in colorless to light yellow needles with antitumor activities (7).
    [Show full text]
  • Using Medications, Cosmetics, Or Eating Certain Foods Can Increase Sensitivity to Ultraviolet Radiation
    USING MEDICATIONS, COSMETICS, OR EATING CERTAIN FOODS CAN INCREASE SENSITIVITY TO ULTRAVIOLET RADIATION. INDIVIDUALS SHOULD CONSULT A PHYSICIAN BEFORE USING A SUNLAMP, IF THEY ARE TAKING MEDICATIONS. THE ITEMS LISTED ARE POTENTIAL PHOTOSENSITIZING AGENTS THAT MAY INCREASE SENSITIVITY TO ULTRAVIOLET LIGHT THAT MAY RESULT IN A PHOTOTOXIC OR PHOTOALLERGIC RESPONSES. PHOTOSENSITIZING MEDICATIONS Acetazolamide Amiloride+Hydrochlorothizide Amiodarone Amitriptyline Amoxapine Astemizole Atenolol+Chlorthalidone Auranofin Azatadine (Optimine) Azatidine+Pseudoephedrine Bendroflumethiazide Benzthiazide Bromodiphenhydramine Bromopheniramine Captopril Captopril+Hydrochlorothiazide Carbaamazepine Chlordiazepoxide+Amitriptyline Chlorothiazide Chlorpheniramine Chlorpheniramin+DPseudoephedrine Chlorpromazine Chlorpheniramine+Phenylopropanolamine Chlorpropamide Chlorprothixene Chlorthalidone Chlorthalidone+Reserpine Ciprofloxacin Clemastine Clofazime ClonidineChlorthalisone+Coal Tar Coal Tar Contraceptive (oral) Cyclobenzaprine Cyproheptadine Dacarcazine Danazol Demeclocycline Desipramine Dexchlorpheniramine Diclofenac Diflunisal Ditiazem Diphenhydramine Diphenylpyraline Doxepin Doxycycline Doxycycline Hyclate Enalapril Enalapril+Hydrochlorothiazide Erythromycin Ethylsuccinate+Sulfisoxazole Estrogens Estrogens Ethionamide Etretinate Floxuridine Flucytosine Fluorouracil Fluphenazine Flubiprofen Flutamide Gentamicin Glipizide Glyburide Gold Salts (compounds) Gold Sodium Thiomalate Griseofulvin Griseofulvin Ultramicrosize Griseofulvin+Hydrochlorothiazide Haloperidol
    [Show full text]
  • Substituent Effect on Aggregation Behavior and DNA Binding
    International Journal of Molecular Sciences Article Arylamine Analogs of Methylene Blue: Substituent Effect on Aggregation Behavior and DNA Binding Alena Khadieva 1, Olga Mostovaya 1, Pavel Padnya 1,* , Valeriy Kalinin 1 , Denis Grishaev 2, Dmitrii Tumakov 3 and Ivan Stoikov 1,* 1 A.M. Butlerov’ Chemistry Institute of Kazan Federal University, 18 Kremlyovskaya Str., 420008 Kazan, Russia; [email protected] (A.K.); [email protected] (O.M.); [email protected] (V.K.) 2 Scientific and Educational Center of Pharmaceutics, Kazan Federal University, 420008 Kazan, Russia; [email protected] 3 Institute of Computational Mathematics and Information Technologies, Kazan Federal University, 420008 Kazan, Russia; [email protected] * Correspondence: [email protected] (P.P.); [email protected] (I.S.); Tel.: +7-(843)-233-7241 (I.S.) Abstract: The synthesis of new phenothiazine derivatives, analogs of Methylene Blue, is of par- ticular interest in the design of new drugs, as well as in the development of a new generation of agents for photodynamic therapy. In this study, two new derivatives of phenothiazine, i.e., 3,7-bis(4-aminophenylamino)phenothiazin-5-ium chloride dihydrochloride (PTZ1) and 3,7-bis(4- sulfophenylamino)phenothiazin-5-ium chloride (PTZ2), are synthesized for the first time and char- acterized by NMR, IR spectroscopy, HRMS and elemental analysis. The interaction of the obtained compounds PTZ1 and PTZ2 with salmon sperm DNA is investigated. It is shown by UV-Vis spec- troscopy and DFT calculations that substituents in arylamine fragments play a crucial role in dimer Citation: Khadieva, A.; Mostovaya, formation and interaction with DNA.
    [Show full text]
  • Stability and Structural Features of DNA Intercalation with Ethidium Bromide, Acridine Orange and Methylene Blue
    ARTICLE IN PRESS Journal of Molecular Structure xxx (2006) xxx–xxx www.elsevier.com/locate/molstruc Stability and structural features of DNA intercalation with ethidium bromide, acridine orange and methylene blue Shohreh Nafisi a,*, Ali Akbar Saboury b, Nahid Keramat a, Jean-Francois Neault c, Heidar-Ali Tajmir-Riahi c a Deparment of Chemistry, Azad University, Central Tehran Branch, 14169 63316 Tehran, Iran b Institute of Biochemistry and Biophysics, University of Tehran, Tehran, Iran c Department of Chemistry and Biology, University of Quebec at Trois-Rivieres, C.P. 500, TR, Que., Canada G9A 5H7 Received 1 March 2006; received in revised form 27 April 2006; accepted 2 May 2006 Abstract Ethidium bromide (EB), acridine orange (AO), methylene blue (MB) and other fluorescent compounds are often used to probe DNA structure in drug–DNA and protein–DNA interactions. They bind nucleic acids via intercalative mode and cause major changes to DNA and RNA structures. The aim of this study was to examine the stability and structural features of calf-thymus DNA complexes with EB, AO and MB in aqueous solution, using constant DNA concentration (12.5 mM) and various pigment/DNA(P) ratios of 1/40, 1/20, 1/ 10, 1/4 and 1/2. FTIR, UV–visible spectroscopy and isothermal titration calorimetry (ITC) are used to determine the ligand intercalation and external binding modes, the binding constant and the stability of pigment–DNA complexes in aqueous solution. Structural analysis showed major intercalation of EB, AO and MB into polynucleotides G–C and A–T base pairs with minor external binding and overall bind- 4 À1 4 À1 4 À1 ing constants of KEB = 6.58 · 10 M , KAO = 2.69 · 10 M and KMB = 2.13 ·10 M .
    [Show full text]
  • Acridine and Phenothiazine Derivatives As Pharmacotherapeutics for Prion Disease
    Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease Carsten Korth*, Barnaby C. H. May†, Fred E. Cohen*†‡§, and Stanley B. Prusiner*ʈ‡¶ *Institute for Neurodegenerative Diseases and Departments of †Cellular and Molecular Pharmacology, ‡Biochemistry and Biophysics, §Medicine, and ¶Neurology, University of California, San Francisco, CA 94143 Contributed by Stanley B. Prusiner, June 1, 2001 Prion diseases in humans and animals are invariably fatal. Prions hibit PrPSc formation, including Congo red, have been identified are composed of a disease-causing isoform (PrPSc) of the normal by using scrapie-infected cultured cells (19–21). Some of these host prion protein (PrPC) and replicate by stimulating the conver- compounds have been examined in rodents but none have been sion of PrPC into nascent PrPSc. We report here that tricyclic effective when given around the time that neurologic signs derivatives of acridine and phenothiazine exhibit half-maximal appear (22). Sc inhibition of PrP formation at effective concentrations (EC50) In a search for compounds that might prove effective in between 0.3 ␮M and 3 ␮M in cultured cells chronically infected treating prion diseases, we have used scrapie-infected neuro- ␮ with prions. The EC50 for chlorpromazine was 3 M, whereas blastoma (ScN2a) cells to screen for inhibition of nascent PrPSc quinacrine was 10 times more potent. A variety of 9-substituted, formation as well as the clearance of preexisting PrPSc. Based on acridine-based analogues of quinacrine were synthesized, which the demonstration that PrPSc formation occurs in cholesterol- demonstrated variable antiprion potencies similar to those of rich microdomains, inhibitors of cholesterol biosynthesis were chlorpromazine and emphasized the importance of the side chain examined for their ability to inhibit the conversion of PrPC into in mediating the inhibition of PrPSc formation.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]